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Abstract: Synthesis of eleven tacrine analogues derived from N-aryl-5-amino-4-
cyanopyrazoles, by a Friedländer type reaction, is described. Their structures were 
confirmed by 1H and 13C NMR spectroscopy, elemental analysis and/or mass 
spectrometry. 
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INTRODUCTION  
The Alzheimer disease (AD) is very common nowadays in elderly individuals. The 
finding that in those patients there is acetylcholine deficiency, is the basis for research 
related to drugs that will inhibit acetylcholinesterase (AChE). The first of these inhibitors 
that received regulatory approval for AD treatment was tacrine (1).[1,2] Modifications 
have also been performed within the structure, either by increasing the number of rings or 
changing their size or introducing heteroatoms.  
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One group found out that compounds with four rings were less active than tacrine against 
AChE, however they were more selective and have shown potential against β-amyloid 
protein aggregation in the brain.[3] 
Tacrine analogues containing a furan ring have been known for some time,[4] and recently, 
Kirsch et al. synthesized analogues of tacrine and velnacrine containing thiophene.[5] An 
analogue of tacrine was also described, in which the primary amino group was replaced 
by the azetidine moiety.[6] 
A Spanish-Portuguese group has described the synthesis of tacrine analogues containing 
heterocyclic rings, such as pyridine, pyran and oxazole, and their inhibitory effects on 
AChE and butyrylcholinesterase.[7] 
Other families of tacrine analogues, containing pyrazolopyridine (e.g 2) or 
pyrazolonaphthyridine (e.g. 3) systems as isosteres of the quinoline ring of tacrine, has 
been described by Barreiro et al.[8] They concluded that compounds 2 and 3 were, in their 
class, the most potent inhibitors of AChE.  
We report here the synthesis of new tacrine analogues from 5-amino-4-cyano-1-
arylpyrazoles by reaction of an ortho-aminonitrile with a cyclic ketone in the presence of 
a Lewis acid. 
RESULTS AND DISCUSSION 
We have been interested for some time on ortho-aminocyanopyrazoles, such as 4, or their 
derivatives, as dye precursors[9] or xanthine oxidase inhibitors.[10] It was decided to 
prepare derivatives of the type 5 or similar, which would be positional isomers of tacrine 
analogue 2 (Scheme 1).  
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Scheme 1 
Most published works build the system using the Friedländer synthesis of 
tetrahydroquinoline.[11] 
In the first approach, we applied the conditions common to many authors[2,3] with 
dichloroethane, AlCl3 and reflux for 6 h under argon (method A). One slight modification 
that we also applied includes heating for 6 h at 150 ºC without solvent and AlCl3 as the 
catalyst (method B). Finally conditions of heterogeneous or solid phase catalysis12 were 
applied, with mixtures of ZnCl2 and silica in proportions 2:1 and 4:1, heating for 4 h at 
150ºC (methods C and D).  
The compounds were obtained in low yields, except for compound 5d either with AlCl3 
(method B, 80%) or ZnCl2 (method C, 60%). For this compound the yield dropped to 
33% when method D (4:1 ZnCl2 and silica) was used. 
We observed that a less polar intermediate was quickly formed, possibly the Schiff’s base, 
but the cyclization was difficult. If we think on the mechanism it is possible to assume 
that the acid will accelerate the formation of the imine. However the closing step may be 
easier when basic catalysis is applied.   
One method reported by Kirsch,[5] obtained the imine, from the aminocyanothiophene 
and 1,3-dicyclohexanedione, in toluene and p-toluenesulphonic acid and cyclised it to the 
tacrine analogue in DMF solution with sodium methoxide and CuCl. Our attempt to 
obtain the imine from the aminocyanopyrazole and cyclohexanone by this method was 
not successful. 
The newly synthesized compounds were identified by 1H, 13C NMR, mass spectra and/or 
elemental analysis (cf. Experimental). 
 
EXPERIMENTAL 
General. Melting points were determined on a Gallenkamp melting point apparatus and 
are uncorrected. IR spectra were registered on a Perkin Elmer FTIR-1600. 1H NMR (300 
MHz) and 13C NMR (75.4 MHz) spectra were recorded on a Varian Unity Plus 
Spectrometer. Double resonance, HMQC and HMBC experiments were carried out for 
complete assignment of proton and carbon signals in the NMR spectra, whenever 
possible. Mass spectra were obtained on a AutoSpec E spectrometer. Elemental analyses 
were obtained on a Leco CHNS-932 instrument. 
Method A- A solution of the p-chlorophenylpyrazole (4d) (0.7 mmol) in dichloroethane 
(25 mL), cyclohexanone (0.1 mL, 0.97 mmol) and AlCl3 (0.1 g, 0.75 mmol) were added 
and the mixture was refluxed for 6 h, under argon. After cooling, a mixture of THF/H2O 
(1:1, 25 mL) was added, and then an aqueous solution of NaOH (10%) was added 
dropwise until the aqueous solution was basic. After stirring for 30 min the mixture was 
extracted with dichloromethane (3 x 20 mL) and the combined extracts were washed with 
brine (20 mL) and dried (MgSO4), filtered and the solvent was evaporated to give a solid  
which was purified by PLC (CH2Cl2-MeOH, 9:1) yield 32%. 
Method B- To a sealed tube (screw cap) the pyrazole derivative (0.3 mmol), 
cyclohexanone (2.0 mmol) and AlCl3 (0.1 g) were added. The mixture was heated for 6 h 
(external temperature 150ºC), while a colour change occurs. After cooling, a mixture of 
THF/H2O (1:1, 5mL) was added, and then an aqueous solution of NaOH (10%) was 
added dropwise until the aqueous solution was basic. After stirring for 30 minutes the 
mixture was extracted with dichloromethane (4 x 10 mL) the combined extracts were 
washed with brine (20 mL) and dried (MgSO4). Concentration of the extract followed by 
chromatography yielded the target compound.  
Methods C and D  
Preparation of the catalyst ZnCl2 / siliga gel  
A mixture of ZnCl2 (8g), siliga gel  (4g, silica gel 60, 0.063 mm, Merck) and water (3 
mL) was stirred for 15 min, left in the oven for 3 h at 80ºC and then 15 h at 150ºC. The 
catalyst (ZnCl2 / siliga gel (2:1)) was cooled and kept in the desiccator (method C).[12,13] 
The catalyst ZnCl2 / siliga gel (4:1) was prepared in a similar manner, using ZnCl2 (8 g) 
and sílica (2 g) (method D). 
Reaction with the catalyst ZnCl2 / siliga gel  
In a screw cap tube was added the pyrazole (0.20 mmol), the catalyst 2:1 or 4:1 (0.55 g, 
and 0.31 g, respectively) and the cyclic ketone (cyclohexanone (0.1 mL, 0.97 mmol). The 
mixture was heated for 4 h at 150ºC. After cooling ethyl acetate (50 mL) was added and 
the mixture was filtered.  The filtrate was washed with saturated sodium bicarbonate 
solution (2 x 20 mL), dried (MgSO4) and evaporated to give an oil that was submitted to 
chromatography. 
Data 
1-Phenyl-5,6,7,8-tetrahydro-1H-pyrazolo[3,4-b]quinolin-4-amine (5a): The title 
compound was obtained by method A as a beige solid (32%); mp 195-197 ºC; δH 
(DMSO-d6): 8.33 (s, 3H, H-3), 8.40-8.29 (m, 2H, H-2’ and 6’), 7.47 (t, 2H, J = 7.2 Hz, 
H-3’ and 5’), 7.21 (t, 1H, J = 7.5 Hz, H-4’), 6.68 (br s, 2H, NH2), 2.85-2.74 (m, 2H, H-8), 
2.52-2.40 (m, 2H, H-5), 1.85-1.71 (m, 4H, H-7 and H-6); δC (DMSO-d6): 157.05 (C-8a), 
150.07 (C-4), 146.99 (C-9a), 140.28 (C-1’), 132.94 (C-3), 128.84 (C-3’ and 5’), 124.53 
(C-4’), 119.45 (C-2´and 6´), 106.83 (C-4a), 105.05 (C-3a), 33.78 (C-8), 22.92 (C-5), 
22.72 and 22.53 (C-7 and C-6). Anal. calcd for C16H16N4: C, 72.73; H, 6.06; N, 21.21. 
Found: C, 72.83; H, 6.16; N, 20.83. 
 
1-p-Tolyl-5,6,7,8-tetrahydro-1H-pyrazolo[3,4-b]quinolin-4-amine (5b): The compound 
was obtained by method B as an off-white solid in 40% yield mp 174-176 ºC; δH 
(DMSO-d6): 8.28 (s, 1H, H-3), 8.18 (d, 2H, J = 8.4 Hz, H-2’ and 6’ or H-3’ and 5’), 7.28 
(d, 2H, J = 8.7 Hz, H3’ and 5’ or H-2’ and 6’), 6.63 (br s 2H, NH2), 2.85-2.74 (m, 2H, H-
8), 2.50-2.40 (m, 2H, H-5), 2.32 (s, 3H, Me), 1.85-1.70 (m, 4H, H-7 and H-6). δC 
(DMSO-d6): 156.99 (C-8a), 149.89 (C-4), 146.93 (C-9a), 137.93 (C-1’), 133.67 (C-3), 
132.51 (C-4’), 129.25 (C-3’ and 5’), 119.56 (C-2´and 6´), 106.63 (C-4a), 104.95 (C-3a), 
33.79 (C-8), 22.92 (C-5), 22.74 and 22.55 (C-7 and C-6), 20.53 (Me). Anal. calcd for 
C17H18N4 ¼H2O: C, 72.18; H, 6.59; N, 19.80. Found: C, 72.19; H, 6.45; N, 19.58. 
 
1-(4-Methoxyphenyl)-5,6,7,8-tetrahydro-1H-pyrazolo[3,4-b]quinolin-4-amine (5c): The 
compound was prepared by method B and obtained as an off-white solid (44%, m.p. 106-
108 ºC; δH (400 MHz, CDCl3): 8.12 (d, 2H, J = 7.0 Hz, H-2’ and 6’), 7.97 (s, 1H, H-3), 
7.01 (d, 2H, J = 6.8 Hz, H-3’ and 5’), 4.61 (br s, 2H, NH2), 2.98 (t, 2H, J = 6.0 Hz, H-8), 
2.54 (t, 2H, J = 6.0 Hz, H-5), 2.0-1.80 (m, 4H, H-7 and H-6); δC (CDCl3): 158.51 (C-8a), 
157.40 (C-4’), 149.76 (C-4), 144.85 (C-9a), 133.46 (C-1’), 129.78 (C-3), 122.72 (C-
2´and 6´), 114.12 (C-3’ and 5’), 107.40 (C-4a), 105.23 (C-3a), 55.51 (OMe), 34.16 (C-8), 
22.93 (C-5), 22.88 and 22.87 (C-7 and C-6). The compound was left to crystallize from 
the NMR solution and it was used for elemental analysis. HRMS calcd for C17H18N4O: 
294.1481; found: (M)+ 294.1482. 
 
1-(4-Chlorophenyl)-5,6,7,8-tetrahydro-1H-pyrazolo[3,4-b]quinolin-4-amine (5d): The 
compound was obtained by methods B, C and D (80, 60 and 33%, respectively) as a 
beige solid, mp 150-152 ºC; δH (DMSO-d6): 8.41 (d, 2H, J = 7.0 Hz, H-2’ and 6’), 8.34 (s, 
1H, H-3), 7.52 (d, 2H, J = 7.0 Hz, H-3’ and 5’), 6.72 (br s, 2H, NH2), 2.85-2.74 (m, 2H, 
H-8), 2.52-2.42 (m, 2H, H-5), 1.86-1.70 (m, 4H, H-7 and H-6). δC (DMSO-d6): 157.15 
(C-8a), 150.09 (C-4), 147.11 (C-9a), 139.12 (C-1’), 133.45 (C-3), 128.79 (C-3’ and 5’), 
128.34 (C-4’), 120.61 (C-2´and 6´), 107.08 (C-4a), 105.05 (C-3a), 33.73 (C-8), 22.89 (C-
5), 22.65 and 22.45 (C-7 and C-6). m/z (EI/TOF): 297 (43), 300 (M+, 37Cl, 22), 299 (16), 
298 (M+, 35Cl, 100). Anal. cald for C16H15N4Cl: C, 64.32; H, 5.06; N, 18.75. Found: C, 
63.92; H, 4.92; N, 18.36. 
 
1-(4-Bromophenyl)-5,6,7,8-tetrahydro-1H-pyrazolo[3,4-b]quinolin-4-amine (5e): The 
compound was prepared by method B yielding a light brown solid (20%); mp 127-129 
ºC; δH (DMSO-d6): 8.35 (d, 2H, J = 9.0 Hz, H-2’ and 6’), 8.35 (s, 1H, H-3), 7.65 (d, 2H, 
J = 9.0 Hz, H-3’ and 5’), 6.73 (br s, 2H, NH2), 2.87-2.74 (m, 2H, H-8), 2.50-2.40 (m, 2H, 
H-5), 1.90-1.70 (m, 4H, H-7 and H-6); δC (DMSO-d6): 157.24 (C-8a), 150.17 (C-4), 
147.19 (C-9a), 139.57 (C-1’), 133.61 (C-3), 131.78 (C-3’ and 5’), 121.05 (C-2´and 6´), 
116.59 (C-4’), 107.17 (C-4a), 105.12 (C-3a), 33.80 (C-8), 22.95 (C-5), 22.70 and 22.51 
(C-7 and C-6). m/z (EI/TOF): 345 (7), 344 (M+, 81Br, 87), 343 (46), 342 (M+, 79Br, 100), 
341 (37), 316 (17), 314 (17), 261 (9), 235 (7), 121 (11). 
 
1-(4-Chlorophenyl)-6-methyl-5,6,7,8-tetrahydro-1H-pyrazolo[3,4-b]quinolin-4-amine  
(5f): The compound was prepared by method C (38%); mp 185-186 ºC; δH (DMSO-d6): 
8.41 (d, 2H, J = 9.0 Hz, H-2’ and 6’), 8.33 (s, 1H, H-3), 7.53 (d, 2H, J = 9.0 Hz, H-3’ and 
5’), 6.73 (br s, 2H, NH2), 2.84 (t, 2H, J = 4.2 Hz, H-8), 2.70-2.58 (m, 1H, H-5), 2.08-1.76 
(m, 3H, H-5, H-6 and H-7), 1.50-1.30 (m, 1H, H-7), 1.09 (d, 3H, J = 6.3 Hz, Me). δC 
(DMSO-d6): 156.97 (C-8a), 150.23 (C-4), 147.07 (C-9a), 139.14 (C-1’), 133.52 (C-3), 
128.85 (C-3’ and 5’), 128.38 (C-4’), 120.65 (C-2´and 6´), 106.81 (C-4a), 105.04 (C-3a), 
33.46 (C-8), 31.52 (C-5), 30.87 (C-7), 28.77 (C-6), 21.98 (Me). m/z (EI/TOF): 315 (4), 
314 (M+, 37Cl, 22), 313 (18), 312 (M+, 35Cl, 100), 311 (17), 297 (12), 272 (15), 270 (79). 
HRMS: 312.1133 (M+, C17H17N435Cl; calc. 312.1142). 314.1114 (M+, C17H17N437Cl; calc. 
314.1112). 
 
1-(4-Trifluoromethylphenyl)-5,6,7,8-tetrahydro-1H-pyrazolo[3,4-b]quinolin-4-amine 
(5g): The compound was obtained by methods A (16%), mp 115-118 ºC; δH (DMSO-d6): 
8.65 (d, 2H, J = 8.4 Hz, H-2’ and 6’), 8.40 (s, 3H, H-3), 7.85 (d, 2H, J = 8.7 Hz, H-3’ and 
5’), 6.78 (br s, 2H, NH2), 2.88-2.78 (m, 2H, H-8), 2.52-2.42 (m, 2H, H-5), 1.86-1.74 (m, 
4H, H-7 and H-6); δC (DMSO-d6): 157.35 (C-8a), 150.55 (C-4), 147.28 (C-9a), 143.30 
(C1´), 134.45 (C-3), 126.21 (C-3’ and 5’), 122.61, 126.17, 129.80 (the other peak of the q 
is hidden under C-2´ and C-6´, 1J = 272.9 Hz, CF3), 124.32 (q, 2J = 31.9 Hz, C-4´), 
118.92 (C-2´and 6´), 107.59 (C-4a), 105.21 (C-3a), 33.75 (C-8), 22.91 (C-6 or C-7), 
22.63 (C-5), 22.43 (C-6 or C-7).  ESI: 333.25 (M+1)+; EI/TOF:  333.13 (15, (M+1)+), 
332.13 (100,  (M)+),  331.13 (64), 304 (32), 303 (16). 
 
1-(3-Chlorophenyl)-5,6,7,8-tetrahydro-1H-pyrazolo[3,4-b]quinolin-4-amine (5h): The 
compound was obtained in 15% yield by method A as a beige solid; mp 199-201 ºC; δH 
(CDCl3): 8.45 (t, 1H, J = 2.6 Hz, H-2’), 8.34 (ddd, 1H, J = 1.2, 2.5, 10.9 Hz, H-4´), 7.99 
(s, 1H, H-3), 7.20 (ddd, 1H, J = 1.2, 2.4, 10.4 Hz, H-6´), 7.41 (t, 1H, J = 10.4 Hz, H-5’), 
4.62 (br s, 2H, NH2), 2.30 (t, 2H, J = 8.0 Hz, H-8), 2.53 (t, 2H, J = 7.6 Hz, H-5), 1.90-
2.00 (m, 4H, H-6 and H-7); δC (CDCl3): 158.77 (C-8a), 150.22 (C-9a), 144.94 (C-4), 
141.21 (C-3´), 134.50 (C-1´), 130.99 (C-3), 129.90 (C-5´), 124.98 (C-6´), 120.43 (C-2´), 
118.35 (C-4’), 108.05 (C-4a), 105.54 (C-3a), 34.15 (C-8), 22.85 (C-6 and C-7), 22.79 (C-
5). Anal. calcd for C16H15ClN4: C, 64.32; H, 5.06; N, 18.75. Found: C, 63.94; H, 5.00; N, 
18.37. m/z (EI/TOF): 300 (M+, 37Cl, 22), 298 (M+, 35Cl, 100). 
 
1-(4-Chlorophenyl)-1,5,6,7-tetrahydrocyclopenta[e]pyrazolo[3,4-b]pyridin-4-amine (6d): 
The compound was prepared by methods A (15%) and B (27%), mp 289-290 ºC. δH 
(DMSO-d6): 8.37 (d, 2H, J = 9.0 Hz, H-2’ and 6’), 8.30 (s, 1H, H-3), 7.54 (d, 2H, J = 9.0 
Hz, H-3’ and 5’), 6.80 (br s, 2H, NH2), 2.88 (t, 2H, J = 7.8 Hz, H-7), 2.71 (t, 2H, J = 7.5 
Hz, H-5), 2.03 (quintet, 2H, J = 7.5 Hz, H-6); δC (DMSO-d6): 166.57 (C-7a), 152.47 (C-
4), 144.91 (C-8a), 139.05 (C-1’), 133.50 (C-3), 128.87 (C-3’ and 5’), 128.61 (C-4’), 
120.96 (C-2´and 6´), 111.62 (C-4a), 105.66 (C-3a), 34.57 (C-7), 26.71 (C-5), 22.57 (C-6). 
m/z -EI/TOF: 286.06 (M+, 37Cl, 22), 285.09 (14), 284.07 (M+, 35Cl, 100), 283.06 (64), 
265.98 (95), 189.99 (92), 121 (80). Anal. calcd for C15H13ClN4: C, 63.27; H, 4.60; N, 
19.68. Found: C, 63.09; H, 4.79; N, 19.10. 
 
1-(4-Trifluoromethylphenyl)-1,5,6,7-tetrahydrocyclopenta[e]pyrazolo[3,4-b]pyridin-4-
amine (6g): The compound was prepared by method A (31%) as a light brown solid, mp 
265-268 ºC; δH (DMSO-d6): 8.62 (d, 2H, J = 8.7 Hz, H-2’ and 6’), 8.37 (s, 1H, H-3), 7.85 
(d, 2H, J = 8.4 Hz, H-3’ and 5’), 6.84 (br s, 2H, NH2), 2.90 (t, 2H, J = 7.5 Hz, H-7), 2.73 
(t, 2H, J = 7.5 Hz, H-5), 2.07 (quintet, 2H, J = 7.5 Hz, H-6); δC (DMSO-d6): 166.33 (C-
7a), 152.89 (C-8a), 145.01 (C-4), 143.21 (C-1’), 134.41 (C-3), 126.18 (C-3´and 5´), 
124.50 (q, 2J = 31.8 Hz, C-4´), 122.58, 126.18, 129.89 (the other peak of the q is hidden 
under C2´ and C-6´, 1J = 274.5 Hz, CF3), 119.19 (C-2´and 6´), 112.05 (C-4a), 105.82 (C-
3a), 34.57 (C-7), 26.70 (C-5), 22.52 (C-6). HRMS calcd for C16H13F3N4: 318.1092; 
found: (M)+ 318.1096. 
 
1-(3-Chlorophenyl)-1,5,6,7-tetrahydrocyclopenta[e]pyrazolo[3,4-b]pyridin-4-amine (6h): 
The compound was prepared by method A (15%) as a light brown solid; mp 233.5-235 
ºC; δH (400 MHz, CDCl3): 8.38 (t, 1H, J = 2.4 Hz, H-2’), 8.29 (ddd, 1H, J = 1.2, 1.8, 8.3 
Hz, H-4´), 8.01 (s, 1H, H-3), 7.22 (ddd, 1H, J= 0.8, 2.2, 8.1 Hz, H-6´), 7.41 (t, 1H, J = 
8.0 Hz, H-5’), 4.54 (br s, 2H, NH2), 3.08 (t, 2H, J = 7.6 Hz, H-7), 2.80 (t, 2H, J = 7.6 Hz, 
H-5), 2.23 (quintet, 2H, J = 7.6 Hz, H-6); δC (CDCl3): 168.11 (C-7a), 152.65 (C-8a), 
142.71 (C-4), 141.10 (C-1’), 134.58 (C-3’), 131.03 (C-3), 129.96 (C-6´), 125.32 (C-5´), 
120.93 (C-2´), 118. 83 (C-4’), 112.93 (C-4a), 106.07 (C-3a), 35.00 (C-7), 26.37 (C-5), 
23.14 (C-6). Anal. calcd for C15H13ClN4: C, 63.27; H, 4.60; N, 19.68. Found: C, 63.22; H, 
4.62; N, 18.29. EI/TOF: 284.08 (M+, 35Cl, 100), 286.08 (M+, 37Cl, 26). 
ACKNOWLEDGEMENTS 
We thank Fundação para a Ciência e Tecnologia and FEDER (POCTI-SFA-3-686; and 
post-Doctoral grant for A. Salaheldin (SFRH/BPD/31490/2006). 
REFERENCES  
1. Valenti, P.; Rampa, A.; Bisi, A.; Andrisano, V.; Cavrini, V.; Fin, L.; Buriani, A.; 
Giusti, A. Acetylcholinesterase inhibition by tacrine analogues. Bioorg. Med. Chem. 
Lett., 1997, 7, 2599. 
2. Martinez-Grau, A.; Marco, J. L. Friedländer reaction on 2-amino-3-cyano-4H-
pyrans: Synthesis of derivatives of 4H-pyran [2,3-b] quinoline, new tacrine 
analogues. Bioorg. Med. Chem. Lett., 1997, 7, 3165. 
3. Marco-Contelles, J.; Leon, R.; Lopez, M. G.; Garcia, A. G.; Villarroya, M. Synthesis 
and biological evaluation of new 4H-pyrano[2,3-b]quinoline derivatives that block 
acetylcholinesterase and cell calcium signals, and cause neuroprotection against 
calcium overload and free radicals. Eur. J. Med. Chem., 2006, 41, 1464.  
4. Chaki, H.; Yamabe, H.; Sugano, M.; Morita, S.; Bessho, T.; Tabata, R.; Saito, K. I.; 
Egawa, M.; Tobe, A.; Morinaka, Y. Design and syntheses of 4-acylaminopyridine 
derivatives: Novel high affinity choline uptake enhancers II. Bioorg. Med. Chem. 
Lett., 1995, 5, 1495. 
5. Thomae, D.; Kirsch, G.; Seck, P. Synthesis of thiophene analogues of the tacrine 
series. Synthesis 2007, 1027. 
6. Michalson, E. T.; D´Andrea, S.; Freeman, J. P.; Szmuszkovicz, J. The Synthesis of 
9-(1-Azetidinyl)-1,2,3,4-tetrahydroacridine. Heterocycles, 1999, 30, 415. 
7. Marco, J. L.; Rios, C.; Garcia, A. G.; Villarroya, M.; Carreiras, M. C.; Martins, C.; 
Eleutério, A.; Morreale, A.; Orozco, M.; Luque, F. Synthesis, biological evaluation 
and molecular modeling of diversely functionalized heterocyclic derivatives as 
inhibitors of acetylcholinesterase/butyrylcholinesterase and modulators of Ca2+ 
channels and nicotinic receptors. Bioorg. Med. Chem., 2004, 12, 2199.  
8. Barreiro, E. J.; Câmara, C. A.; Verli, H.; Brazil-Más, L.; Castro, N. G.; Cintra, W. 
M.; Aracava, Y.; Fraga, C. A. M. Design, Synthesis, and Pharmacological Profile of 
Novel Fused Pyrazolo[4,3-d]pyridine and Pyrazolo[3,4-b][1,8]naphthyridine 
Isosteres: A New Class of Potent and Selective Acetylcholinesterase Inhibitors. J. 
Med. Chem., 2003, 46, 1144. 
9. Gupta, S.; Sivasubramanian, A.; Rodrigues, L. M.; Esteves, A. P.; Hrdina, R.; 
Oliveira-Campos, A. M. F. synthesis of dyes derived from 1-aryl-5-amino-4-
cyanopyrazoles. Dyes and Pigments, 2007, 75, 82-87. 
10. Gupta S.; Rodrigues, L. M.; Esteves, A. P.; Oliveira-Campos, A. M. F.; Nascimento, 
M. S. J.; Nazareth, N.; Cidade, H.; Neves, M. P.; Pinto, E. F. M.; Cerqueira, N. M. F. 
and Brás N. Synthesis of N-aryl-5-amino-4-cyanopyrazole derivatives as potent 
xanthine oxidase inhibitors. Eur. J. Med. Chem. 2008, 43, 771. 
11. Cheng, C. C.; Yan, S. J. Org. Reactions, Vol. 28, John Wiley & Sons, New York, 
1982, pp. 37-201.  
12. Barbosa, S. L.; Dabdoub, M. J.; Hurtado, G. R.; Klein, S. I.; Baroni, A. C. M.; 
Cunha, C. Solvent free esterification reactions using Lewis acids in solid phase 
catalysis. Applied Catalysis A: General, 2006, 313, 146. 
13. Jacob, R. G.; Perin, G.; Loi, L. N.; Pinno, C. S.; Lenardão, E. J. Green synthesis of 
(−)-isopulegol from (+)-citronellal: application to essential oil of citronella  
Tetrahedron Lett., 2003, 44, 3605. 
 
